1. New and Emerging Management Options for Anemia in CKD

2. CKD Prevalence by Stage

3. Relationship Between CKD and CVD

4. Graded and Independent Relationship Between Estimated GFR and CVD Outcomes*

5. Patients Diagnosed With CKD Have a Greater Likelihood of Death Than Patients With ESRD

6. Cardiovascular Mortality Is Higher in Patients With ESRD

7. Anemia as a Complication of CKD

8. Definition of Anemia in CKD

9. Role of the Kidney in Erythropoiesis

10. Factors That Contribute to Anemia in CKD

11. Prevalence of Anemia* in Patients With CKD by GFR

12. Anemia Is an All-Cause Mortality Multiplier: Medicare Beneficiaries

13. Cardiorenal Failure Target Anemia

14. Impact of Anemia in Patients With CKD Stage 5

15. Impact of Anemia in Patients With CKD Stage 3-4

16. Management of Anemia in CKD KDOQI Guidelines

17. Perspective

18. Hb Levels Should Be Evaluated in ALL CKD Patients, Regardless of Stage*

19. Mean Monthly Hemoglobin And Mean EPO Dose per Week Higher Hb With Concomitant Increase in Use of Drugs

20. Published Randomized Controlled Trials in CKD The Bottom Line

21. Anemia Correction in CKD Impact on Quality of Life

22. Great Unknown!

23. Next Big Question!

24. Rationale for New Approaches in CKD Anemia

25. New Drugs HIF-PHI

26. Role of HIF-PHI in Iron-Restricted, EPO-Deficient Anemias

27. Prolyl Hydroxylase Inhibitors (HIF Agonists) in Active Clinical Development

28. Roxadustat Elevates Hb in Stage III-IV CKD Anemia

29. Roxadustat Elevates Hb With Lesser Decline in Serum Iron as Compared With Epoetin

30. Roxadustat Achieves Target Hb Within or Near Physiologic EPO Cmax Levels

31. Hb Response to Oral Roxadustat TIW Without IV Iron in Dialysis-Dependent CKD

32. Vadadustat Phase 2b -- Hb and Hepcidin Levels

33. Vadadustat Phase 3 Studies

34. Daprodustat Phase 2 Change in Hb and EPO levels After Conversion From ESA in DD-CKD

35. Roxadustat No Impact of Inflammation on Efficacy (NDD and DD-CKD)

36. HIF-Stabilizers Safety Concerns

37. HIF-Stabilizers Safety Concerns (cont)

38. Hepcidin Modulation

39. Hepcidin Antagonists

40. Conclusions

41. Abbreviations

42. Abbreviations (cont)

43. Abbreviations (cont)